SE9903028D0 - New use - Google Patents

New use

Info

Publication number
SE9903028D0
SE9903028D0 SE9903028A SE9903028A SE9903028D0 SE 9903028 D0 SE9903028 D0 SE 9903028D0 SE 9903028 A SE9903028 A SE 9903028A SE 9903028 A SE9903028 A SE 9903028A SE 9903028 D0 SE9903028 D0 SE 9903028D0
Authority
SE
Sweden
Prior art keywords
chf
stroke
diabetes
heart failure
congestive heart
Prior art date
Application number
SE9903028A
Other languages
English (en)
Swedish (sv)
Inventor
Gilles Dagenais
Hertzel Gerstein
Anders Ljunggren
Salim Yusuf
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20416770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9903028(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903028A priority Critical patent/SE9903028D0/xx
Publication of SE9903028D0 publication Critical patent/SE9903028D0/xx
Priority to UA2002032397A priority patent/UA76702C2/uk
Priority to MEP-282/08A priority patent/MEP28208A/xx
Priority to EP10010670A priority patent/EP2277519A3/en
Priority to CA002382387A priority patent/CA2382387C/en
Priority to DK04006330.7T priority patent/DK1437131T3/da
Priority to ES08004265.8T priority patent/ES2525699T3/es
Priority to JP2001519887A priority patent/JP4843172B2/ja
Priority to PL00353066A priority patent/PL353066A1/xx
Priority to TR2002/02463T priority patent/TR200202463T2/xx
Priority to ES04006330T priority patent/ES2386141T3/es
Priority to RU2002107673/15A priority patent/RU2272651C2/ru
Priority to EP04006330A priority patent/EP1437131B1/en
Priority to AT04006330T priority patent/ATE554761T1/de
Priority to PT80042658T priority patent/PT1925303E/pt
Priority to HR20020169A priority patent/HRP20020169A2/hr
Priority to BR0013540-2A priority patent/BR0013540A/pt
Priority to TR2002/02466T priority patent/TR200202466T2/xx
Priority to SI200031069T priority patent/SI1437131T1/sl
Priority to RS3602A priority patent/RS52907B/en
Priority to DK00965898.0T priority patent/DK1212081T4/da
Priority to SI200031084T priority patent/SI1925303T1/sl
Priority to DE60023518.1T priority patent/DE60023518T3/de
Priority to NZ571901A priority patent/NZ571901A/en
Priority to KR1020087007837A priority patent/KR20080035703A/ko
Priority to TR2002/02467T priority patent/TR200202467T2/xx
Priority to SK270-2002A priority patent/SK288239B6/sk
Priority to SI200030766T priority patent/SI1212081T2/sl
Priority to AU76484/00A priority patent/AU7648400A/en
Priority to TR2002/00518T priority patent/TR200200518T2/xx
Priority to CNA2008101259535A priority patent/CN101537181A/zh
Priority to ES00965898.0T priority patent/ES2250192T5/es
Priority to AT00965898T priority patent/ATE307604T1/de
Priority to EP00965898.0A priority patent/EP1212081B2/en
Priority to CZ20020644A priority patent/CZ303433B6/cs
Priority to CNB008110700A priority patent/CN100408093C/zh
Priority to PT04006330T priority patent/PT1437131E/pt
Priority to IL148126A priority patent/IL148126A/en
Priority to HU0202461A priority patent/HU229107B1/hu
Priority to KR1020027002521A priority patent/KR20020060167A/ko
Priority to EEP200200085A priority patent/EE05130B1/xx
Priority to HK03102600.5A priority patent/HK1050327B/xx
Priority to MXPA02001633A priority patent/MXPA02001633A/es
Priority to PCT/EP2000/008341 priority patent/WO2001015673A2/en
Priority to DK08004265.8T priority patent/DK1925303T3/en
Priority to TR2002/02464T priority patent/TR200202464T2/xx
Priority to EP08004265.8A priority patent/EP1925303B1/en
Priority to YU3602A priority patent/YU3602A/sh
Priority to BG106319A priority patent/BG66115B1/bg
Priority to BG11047909A priority patent/BG110479A/bg
Priority to NO20020850A priority patent/NO329245B1/no
Priority to ZA200201471A priority patent/ZA200201471B/xx
Priority to AU2005203694A priority patent/AU2005203694A1/en
Priority to RU2005128124/15A priority patent/RU2378018C2/ru
Priority to UAA200601774A priority patent/UA88270C2/ru
Priority to US11/415,137 priority patent/US20060194868A1/en
Priority to US12/027,938 priority patent/US20080125472A1/en
Priority to AU2009200551A priority patent/AU2009200551B2/en
Priority to US12/457,589 priority patent/US20090258919A1/en
Priority to US12/615,588 priority patent/US20100267798A1/en
Priority to NO20100569A priority patent/NO20100569L/no
Priority to US12/957,777 priority patent/US20110263619A1/en
Priority to CY20121100657T priority patent/CY1112987T1/el
Priority to US13/673,852 priority patent/US20130317047A1/en
Priority to CY20141101082T priority patent/CY1115869T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9903028A 1999-08-27 1999-08-27 New use SE9903028D0 (sv)

Priority Applications (65)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use
UA2002032397A UA76702C2 (uk) 1999-08-27 2000-08-25 Застосування раміприлу для запобігання розвитку застійної серцевої недостатності
MEP-282/08A MEP28208A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
EP10010670A EP2277519A3 (en) 1999-08-27 2000-08-25 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure
CA002382387A CA2382387C (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
DK04006330.7T DK1437131T3 (da) 1999-08-27 2000-08-25 Anvendelse af ramipril til forebyggelse af diabetes hos en patient uden præeksisterende kongestiv hjerteinsufficiens
ES08004265.8T ES2525699T3 (es) 1999-08-27 2000-08-25 Uso de antagonistas del receptor de tipo 1 de la angiotensina II para la prevención de diabetes
JP2001519887A JP4843172B2 (ja) 1999-08-27 2000-08-25 医薬処方物および卒中、糖尿病および／またはうっ血性心不全の予防におけるその使用
PL00353066A PL353066A1 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
TR2002/02463T TR200202463T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
ES04006330T ES2386141T3 (es) 1999-08-27 2000-08-25 Uso de ramipril para la prevención de diabetes en un paciente sin insuficiencia cardíaca congestiva preexistente
RU2002107673/15A RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
EP04006330A EP1437131B1 (en) 1999-08-27 2000-08-25 Use of ramipril for the prevention of diabetes in a patient with no preexisting congestive heart failure
AT04006330T ATE554761T1 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur vorbeugung von diabetes bei einem patienten ohne bestehendes kongestives herzversagen
PT80042658T PT1925303E (pt) 1999-08-27 2000-08-25 Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes
HR20020169A HRP20020169A2 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
BR0013540-2A BR0013540A (pt) 1999-08-27 2000-08-25 Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
TR2002/02466T TR200202466T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar.
SI200031069T SI1437131T1 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje diabetesa pri bolniku brez predhodno obstoječe kongestivne srčne opovedi
RS3602A RS52907B (en) 1999-08-27 2000-08-25 USE OF ACE INHIBITORS FOR THE PREVENTION OF CONGESTIVE HEART INSUFFICIENCY
DK00965898.0T DK1212081T4 (da) 1999-08-27 2000-08-25 Anvendelse af ACE-inhibitorer i forebyggelse af kongestivt hjertesvigt
SI200031084T SI1925303T1 (sl) 1999-08-27 2000-08-25 Uporaba angiotenzin II tip 1 receptorskih antagonistov za preprečevanje diabetesa
DE60023518.1T DE60023518T3 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur prophylaxe von kongestivem herzversagen
NZ571901A NZ571901A (en) 1999-08-27 2000-08-25 Use of ramipril or ramiprilat for the prevention of congestive heart failure
KR1020087007837A KR20080035703A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증 예방용 약제학적조성물
TR2002/02467T TR200202467T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formulasyonlar
SK270-2002A SK288239B6 (sk) 1999-08-27 2000-08-25 Použitie ramiprilu na výrobu liečiva na prevenciu kongestívneho zlyhania srdca
SI200030766T SI1212081T2 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje kongestivne srčne odpovedi
AU76484/00A AU7648400A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
TR2002/00518T TR200200518T2 (tr) 1999-08-27 2000-08-25 Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
CNA2008101259535A CN101537181A (zh) 1999-08-27 2000-08-25 药物制剂及其在预防中风、糖尿病和/或充血性心衰中的应用
ES00965898.0T ES2250192T5 (es) 1999-08-27 2000-08-25 Uso de ramipril en la prevención de la insuficiencia cardiaca congestiva
AT00965898T ATE307604T1 (de) 1999-08-27 2000-08-25 Verwendung von ace inhibitoren zur prophylaxe von kongestivem herzversagen
EP00965898.0A EP1212081B2 (en) 1999-08-27 2000-08-25 Use of ramipril in the prevention of congestive heart failure
CZ20020644A CZ303433B6 (cs) 1999-08-27 2000-08-25 Použití ramiprilu, ramiprilátu nebo jejich farmaceuticky prijatelných derivátu
CNB008110700A CN100408093C (zh) 1999-08-27 2000-08-25 血管紧张素转化酶抑制剂在制备预防或降低充血性心衰的药物中的用途
PT04006330T PT1437131E (pt) 1999-08-27 2000-08-25 Utilização de ramipril para a prevenção de diabetes num doente sem insuficiência cardíaca congestiva pré-existente
IL148126A IL148126A (en) 1999-08-27 2000-08-25 Use of Rampril or Ramiprilat or their pharmaceutical salt preparation to prepare a heart failure medication in patients without previous heart failure
HU0202461A HU229107B1 (en) 1999-08-27 2000-08-25 Use of ramipril in prevention of congestive heart failure
KR1020027002521A KR20020060167A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증의 예방을 위한약제학적 제형 및 이의 용도
EEP200200085A EE05130B1 (et) 1999-08-27 2000-08-25 Angiotensiini konvertaasi inhibiitori kasutamine ravimina kongestiivse sdamepuudulikkuse „rahoidmiseks
HK03102600.5A HK1050327B (en) 1999-08-27 2000-08-25 Use of an angiotensin converting enzyme inhibitor in the manufacture of a medicament for the prevention or reduction of the risk of congestive heart failure
MXPA02001633A MXPA02001633A (es) 1999-08-27 2000-08-25 Formulaciones farmaceuticas y su uso en la prevencion de ataque, diabetes y/o falla cardiaca congestiva.
PCT/EP2000/008341 WO2001015673A2 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
DK08004265.8T DK1925303T3 (en) 1999-08-27 2000-08-25 Use of the angiotensin II type 1 receptor antagonists for the prevention of diabetes
TR2002/02464T TR200202464T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
EP08004265.8A EP1925303B1 (en) 1999-08-27 2000-08-25 Use of Angiotensin II type 1 receptor antagonists for the prevention of diabetes
YU3602A YU3602A (sh) 1999-08-27 2002-01-16 Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primena
BG106319A BG66115B1 (bg) 1999-08-27 2002-01-18 Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
BG11047909A BG110479A (en) 1999-08-27 2002-01-18 Pharmaceutical preparations and their use in the prevention of stroke, diabetes and/or congestive heart failure
NO20020850A NO329245B1 (no) 1999-08-27 2002-02-21 Anvendelse av ramipril eller ramiprilat for fremstilling av medikament
ZA200201471A ZA200201471B (en) 1999-08-27 2002-02-21 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure.
AU2005203694A AU2005203694A1 (en) 1999-08-27 2005-08-17 Pharmaceutical Formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
RU2005128124/15A RU2378018C2 (ru) 1999-08-27 2005-09-08 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
UAA200601774A UA88270C2 (ru) 1999-08-27 2006-02-20 Фармацевтический препарат и его применение для профилактики удара, диабета
US11/415,137 US20060194868A1 (en) 1999-08-27 2006-05-02 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure
US12/027,938 US20080125472A1 (en) 1999-08-27 2008-02-07 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
AU2009200551A AU2009200551B2 (en) 1999-08-27 2009-02-12 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
US12/457,589 US20090258919A1 (en) 1999-08-27 2009-06-16 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure
US12/615,588 US20100267798A1 (en) 1999-08-27 2009-11-10 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
NO20100569A NO20100569L (no) 1999-08-27 2010-04-20 Farmasoytiske formuleringer og anvendelse derav i forebyggelsen av slag, diabetes og/eller kongestivt hjertesvikt
US12/957,777 US20110263619A1 (en) 1999-08-27 2010-12-01 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20121100657T CY1112987T1 (el) 1999-08-27 2012-07-24 Χρηση της ραμιπριλης για την προληψη του διαβητη σε ασθενη χωρις προυπαρχουσα συμφορητικη καρδιακη ανεπαρκεια
US13/673,852 US20130317047A1 (en) 1999-08-27 2012-11-09 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20141101082T CY1115869T1 (el) 1999-08-27 2014-12-23 Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Publications (1)

Publication Number Publication Date
SE9903028D0 true SE9903028D0 (sv) 1999-08-27

Family

ID=20416770

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Country Status (35)

Country Link
US (6) US20060194868A1 (cs)
EP (4) EP1212081B2 (cs)
JP (1) JP4843172B2 (cs)
KR (2) KR20080035703A (cs)
CN (2) CN100408093C (cs)
AT (2) ATE307604T1 (cs)
AU (3) AU7648400A (cs)
BG (2) BG110479A (cs)
BR (1) BR0013540A (cs)
CA (1) CA2382387C (cs)
CY (2) CY1112987T1 (cs)
CZ (1) CZ303433B6 (cs)
DE (1) DE60023518T3 (cs)
DK (3) DK1437131T3 (cs)
EE (1) EE05130B1 (cs)
ES (3) ES2386141T3 (cs)
HR (1) HRP20020169A2 (cs)
HU (1) HU229107B1 (cs)
IL (1) IL148126A (cs)
ME (1) MEP28208A (cs)
MX (1) MXPA02001633A (cs)
NO (2) NO329245B1 (cs)
NZ (1) NZ571901A (cs)
PL (1) PL353066A1 (cs)
PT (2) PT1437131E (cs)
RS (1) RS52907B (cs)
RU (2) RU2272651C2 (cs)
SE (1) SE9903028D0 (cs)
SI (3) SI1925303T1 (cs)
SK (1) SK288239B6 (cs)
TR (5) TR200200518T2 (cs)
UA (2) UA76702C2 (cs)
WO (1) WO2001015673A2 (cs)
YU (1) YU3602A (cs)
ZA (1) ZA200201471B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268331C (zh) * 1999-08-30 2006-08-09 萨诺费－阿文蒂斯德国有限公司 肾素－血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途
US6903111B2 (en) 2001-03-26 2005-06-07 Kotobuki Pharmaceutical Co., Ltd. Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same
CA2463682A1 (en) * 2001-10-17 2003-04-24 Aventis Pharma Deutschland Gmbh Method of reducing type 2 diabetes in high risk patients
US6844361B2 (en) 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
BRPI0409699A (pt) 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
WO2005049035A1 (en) 2003-11-18 2005-06-02 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
EP1817007A2 (en) * 2004-11-05 2007-08-15 King Pharmaceuticals Research and Development Inc. Stabilized individually coated ramipril particles, compositions and methods
CA2675901A1 (en) * 2005-10-13 2007-04-19 Duke University Compositions for the treatment and prevention of heart disease and methods of using same
MX2009002091A (es) * 2006-08-28 2009-03-09 Sanofi Aventis Deutschland Metodos para reducir las concentraciones de glucosa.
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8686038B2 (en) 2008-06-19 2014-04-01 The Univsersity of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CA2733790A1 (en) 2008-08-20 2010-02-25 Ensemble Discovery Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
WO2011014261A1 (en) 2009-07-31 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
JP5647338B2 (ja) 2010-05-14 2014-12-24 サバンジ・ウニヴェルシテシＳａｂａｎｃｉ Ｕｎｉｖｅｒｓｉｔｅｓｉ 流体力学的キャビテーションを治療に利用するための装置
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2016176338A1 (en) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
CN107810187B (zh) 2015-07-07 2020-09-15 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂
CA3000842A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
EP4349403A3 (en) 2018-05-25 2024-06-05 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途
BR112021003686A2 (pt) 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
KR20230137654A (ko) * 2022-03-22 2023-10-05 주식회사 메디포럼 뇌졸중의 예방 및 치료용 조성물

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (cs) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (en) * 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0331014A3 (de) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
CA2003382A1 (en) * 1988-11-21 1990-05-21 Hollis D. Kleinert Method for treating vascular diseases
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DK0955294T3 (da) 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
EP0403158A3 (en) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
HU215834B (hu) 1989-06-30 1999-04-28 E. I. Du Pont De Nemours And Co. Eljárás aromás csoporttal szubsztituált imidazolszármazékok, valamint ezeket hatóanyagként tartalmazó gyógyszerkészítmények előállítására
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EP0412594B1 (en) 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
HUT54991A (en) 1989-08-11 1991-04-29 Ici Plc Process for producing quinoline derivatives and pharmaceutical compositions comprising such compounds
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0424317A3 (en) 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
AU640417B2 (en) 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
IL96019A0 (en) 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (en) 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
EP0430709A3 (en) 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
US5104891A (en) 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2032289A1 (en) 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
WO1991012002A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0517812A4 (en) 1990-02-13 1995-10-18 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991011909A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Triazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0515357B1 (de) 1990-02-14 1996-01-10 Siemens Aktiengesellschaft Verfahren zur demodulation von secam-codierten farbfernsehsignalen mit zeilenverkoppeltem takt und schaltungsanordnung zur durchführung des verfahrens
CA2036304C (en) 1990-02-15 2001-04-17 Takehiko Naka Pyrimidinedione derivatives, their production and use
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
CA2036618C (en) 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
DE4006693A1 (de) 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5044166A (en) 1990-03-05 1991-09-03 Membrane Technology & Research, Inc. Refrigeration process with purge and recovery of refrigerant
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
GB9005354D0 (en) 1990-03-09 1990-05-02 Glaxo Group Ltd Chemical compounds
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
WO1991015209A1 (en) 1990-03-30 1991-10-17 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
EP0523141A4 (en) 1990-03-30 1993-04-21 Merck & Co. Inc. Substituted pyrazoles, isoxazoles and isothiazoles
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
JPH05507469A (ja) 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5098920A (en) 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
CA2041763A1 (en) 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
AU7903091A (en) 1990-05-25 1991-12-31 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
JPH04235974A (ja) 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
ES2121773T3 (es) 1990-06-08 1998-12-16 Hoechst Marion Roussel Inc Derivados de bencimidazol, su procedimiento de preparacion, productos intermedios, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
AU7983691A (en) 1990-06-15 1992-01-07 G.D. Searle & Co. 1h-substituted-imidazo{4,5-d}pyridazine compounds for treatment of cardiovascular disorders
KR100196559B1 (ko) 1990-06-19 1999-06-15 기따사또 이찌로 안지오텐신ii 길항작용을 함유하는 피리딘 유도체
DK0533840T3 (da) 1990-06-22 1996-12-30 Du Pont Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
CA2044806A1 (en) 1990-07-18 1992-01-19 Roland Jaunin Purine derivatives
CA2047029A1 (en) 1990-07-19 1992-01-20 Shieh-Shung T. Chen Microbial transformation process for antihypertensive products
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
RU1836357C (ru) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
NZ239161A (en) 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0470543A1 (de) 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
US5217985A (en) 1990-08-28 1993-06-08 G. D. Searle & Co. Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
AU8405691A (en) 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5140036A (en) 1990-09-19 1992-08-18 G. D. Searle & Co. 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5126342A (en) 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5430145A (en) 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
WO1992007852A1 (en) 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
DE4036706A1 (de) 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9025123D0 (en) 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
GB9026006D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
AU9055391A (en) 1990-11-30 1992-06-25 Smithkline Beecham Corporation Substituted 5-aryl imidazoles
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
AU9137791A (en) 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5175180A (en) 1990-12-20 1992-12-29 G. D. Searle & Co. N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders
CA2058198A1 (en) 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
DE69221175T2 (de) 1991-02-07 1998-01-15 Roussel Uclaf Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
GB9102803D0 (en) 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
FI112942B3 (fi) 1991-02-21 2012-03-13 Daiichi Sankyo Co Ltd Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
FR2673427B1 (fr) 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
EP0503838A3 (en) 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
EP0505098A1 (en) 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
AU1417092A (en) 1991-03-25 1992-10-21 Glaxo Group Limited 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5155117A (en) 1991-04-12 1992-10-13 G. D. Searle & Co. 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
TW274551B (cs) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
CZ227093A3 (en) 1991-04-29 1994-03-16 Merck & Co Inc Mixture suitable for the preparation of tablets by direct moulding
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5162340A (en) 1991-05-10 1992-11-10 Merck & Co., Inc. Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
GB9110532D0 (en) 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110635D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110623D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
EP0514197A1 (en) 1991-05-16 1992-11-19 Glaxo Group Limited Anti-hypertensive benzofuran derivatives substituted by N-imidazolyl-methyl groups which are condensed with optionally nitrogen containing, six-membered rings
EP0514192A1 (en) 1991-05-16 1992-11-19 Glaxo Group Limited Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
WO1992021666A1 (fr) 1991-05-31 1992-12-10 Laboratoires Upsa Derives de thiazole antagonistes de recepteurs a l'angiotensine ii
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5210211A (en) 1991-06-21 1993-05-11 Warner-Lambert Company 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
IL102365A0 (en) 1991-07-03 1993-01-14 Merck & Co Inc Substituted triazolinones,their preparation and pharmaceutical compositions containing them
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1993003033A1 (en) 1991-07-26 1993-02-18 G. D. Searle & Co. CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
AU2390792A (en) 1991-08-05 1993-03-02 Taisho Pharmaceutical Co., Ltd. Thienopyrimidin-4-one derivative
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
DK0528762T3 (da) 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
DE534263T1 (de) 1991-09-20 1993-09-02 L.G.L. Electronics S.P.A., Bergamo Selbstregulierende fadenbremse fuer eine schussfadenliefervorrichtung.
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
ZA927211B (en) 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JPH06107661A (ja) * 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
KR100281450B1 (ko) 1992-05-15 2001-02-01 슈테펜 엘. 네스비트 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체
US5554625A (en) * 1992-07-17 1996-09-10 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
DE4308504A1 (de) * 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
NZ267161A (en) 1993-06-11 1996-12-20 Eisai Co Ltd Dipeptidic benzazepine derivative with ace inhibiting activity
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
JPH11507012A (ja) * 1995-02-10 1999-06-22 ジー．ディー．サール アンド カンパニー 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DE69712338T2 (de) * 1996-06-24 2002-11-07 Merck & Co., Inc. Zusammensetzung auf basis von enalapril und losartan
DK0966282T3 (da) * 1997-01-10 2003-09-29 Merck & Co Inc Anvendelse af angiotensin ll antagonister til behandling af symptomatisk hjerteinsufficiens
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
CA2677910C (en) * 1997-10-17 2011-03-15 Ark Therapeutics Limited The use of inhibitors of the renin-angiotensin system for the treatment of cardiovascular diseases
US6097772A (en) * 1997-11-24 2000-08-01 Ericsson Inc. System and method for detecting speech transmissions in the presence of control signaling
JPH11222439A (ja) * 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
ES2214013T3 (es) * 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
DE19913528A1 (de) * 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
CN1268331C (zh) * 1999-08-30 2006-08-09 萨诺费－阿文蒂斯德国有限公司 肾素－血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
ITBO20030050A1 (it) * 2003-02-06 2004-08-07 Ima Spa Macchina per il trattamento di prodotti farmaceutici.

Also Published As

Publication number Publication date
JP2003508426A (ja) 2003-03-04
RU2378018C2 (ru) 2010-01-10
PL353066A1 (en) 2003-10-06
SK288239B6 (sk) 2015-02-03
US20080125472A1 (en) 2008-05-29
EP1925303B1 (en) 2014-09-24
ME00181B (me) 2010-10-10
TR200202466T2 (tr) 2002-12-23
US20090258919A1 (en) 2009-10-15
BG106319A (bg) 2002-12-29
DK1925303T3 (en) 2015-01-05
NO329245B1 (no) 2010-09-20
RU2005128124A (ru) 2007-03-20
RU2002107673A (ru) 2004-01-10
WO2001015673A3 (en) 2002-03-07
ATE554761T1 (de) 2012-05-15
KR20080035703A (ko) 2008-04-23
CA2382387C (en) 2005-06-21
ZA200201471B (en) 2003-05-28
WO2001015673A2 (en) 2001-03-08
BG66115B1 (bg) 2011-05-31
CY1115869T1 (el) 2017-01-25
SI1212081T2 (sl) 2014-08-29
CA2382387A1 (en) 2001-03-08
IL148126A (en) 2014-12-31
CY1112987T1 (el) 2016-04-13
NO20020850D0 (no) 2002-02-21
DE60023518D1 (de) 2005-12-01
YU3602A (sh) 2004-12-31
EE200200085A (et) 2003-04-15
DE60023518T2 (de) 2006-07-06
ES2386141T3 (es) 2012-08-10
HUP0202461A3 (en) 2003-04-28
CN1384756A (zh) 2002-12-11
NO20100569L (no) 2002-02-21
MEP28208A (en) 2010-10-10
EP1925303A3 (en) 2010-12-08
CZ303433B6 (cs) 2012-09-12
EE05130B1 (et) 2009-02-16
US20130317047A1 (en) 2013-11-28
SI1925303T1 (sl) 2015-01-30
PT1925303E (pt) 2014-12-18
DE60023518T3 (de) 2014-08-28
EP1212081B1 (en) 2005-10-26
HRP20020169A2 (en) 2005-10-31
ES2250192T3 (es) 2006-04-16
EP1437131B1 (en) 2012-04-25
AU2005203694A1 (en) 2005-09-08
CN101537181A (zh) 2009-09-23
TR200202464T2 (tr) 2003-01-21
RU2272651C2 (ru) 2006-03-27
EP1212081B8 (en) 2005-12-28
TR200200518T2 (tr) 2002-06-21
EP1925303A2 (en) 2008-05-28
DK1437131T3 (da) 2012-08-06
AU7648400A (en) 2001-03-26
BG110479A (en) 2010-01-29
HUP0202461A2 (hu) 2002-12-28
PT1437131E (pt) 2012-07-12
EP1212081B2 (en) 2014-04-02
KR20020060167A (ko) 2002-07-16
NZ571901A (en) 2010-05-28
TR200202467T2 (tr) 2002-12-23
EP2277519A3 (en) 2011-09-07
JP4843172B2 (ja) 2011-12-21
HK1050327A1 (zh) 2003-06-20
DK1212081T4 (da) 2014-07-07
UA88270C2 (ru) 2009-10-12
SI1212081T1 (sl) 2006-06-30
EP2277519A2 (en) 2011-01-26
TR200202463T2 (tr) 2003-01-21
BR0013540A (pt) 2002-04-30
CN100408093C (zh) 2008-08-06
EP1212081A2 (en) 2002-06-12
ATE307604T1 (de) 2005-11-15
RS52907B (en) 2014-02-28
ES2250192T5 (es) 2014-06-27
US20110263619A1 (en) 2011-10-27
AU2009200551A1 (en) 2009-03-05
AU2009200551B2 (en) 2010-09-30
SI1437131T1 (sl) 2012-09-28
NO20020850L (no) 2002-02-21
CZ2002644A3 (cs) 2002-05-15
ES2525699T3 (es) 2014-12-29
US20100267798A1 (en) 2010-10-21
HU229107B1 (en) 2013-07-29
IL148126A0 (en) 2002-09-12
SK2702002A3 (en) 2002-09-10
EP1437131A1 (en) 2004-07-14
UA76702C2 (uk) 2006-09-15
US20060194868A1 (en) 2006-08-31
DK1212081T3 (da) 2006-01-16
MXPA02001633A (es) 2002-08-06

Similar Documents

Publication Publication Date Title
SE9903028D0 (sv) New use
UA88265C2 (ru) Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2001082919A3 (en) Methods of and compounds for inhibiting calpains
Whelton et al. Once‐daily lisinopril compared with twice‐daily captopril in the treatment of mild to moderate hypertension: Assessment of office and ambulatory blood pressures
WO2002056837A3 (en) Inhibition of protein-phosphatases for the treatment of heart failure
WO2003032963A3 (en) Method of reducing type 2 diabetes in high risk patients
NO20013753D0 (no) Anvendelse av moxonidin til behandling etter hjerteinfarkt
Bankhead Antihypertensive therapy: friend or foe in stroke?
WO2004075893A8 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
Stergiou et al. A005: Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension
UA37953A (uk) Спосіб поліхіміотерапії вперше виявлених хворих деструктивним туберкульозом легень
AR022475A1 (es) Metodo para la prevencion o reduccion de eventos cardiovasculares asociados con intervencion coronaria.
Golden et al. Three false truths?
OTSUKA et al. A Case of Angioneurotic Edema of the Tongue and Oral Floor Associated with Angiotensin-Converting Enzyme Inhibitor
UA6306U (en) Method for treating disorders of hepatic blood circulation in patients with arterial hypertension and heart failure